Leucovorin Label Clarifies Rescue, Folate Replacement, and 5-FU Potentiation
Leucovorin sits at an unusual intersection of supportive care and anticancer pharmacology. The updated DailyMed label for leucovorin calcium injection frames the drug as a reduced folate that can both protect normal tissues from antifolate injury and intensify the effect of fluoropyrimidines in colorectal cancer. Those two roles are not contradictory; they reflect the same biochemical pathway being used in opposite directions, depending on the drug partner and the clinical setting.
The injectable formulation is supplied as a sterile lyophilized product for intramuscular or intravenous use in 500 mg vials. Each vial, when reconstituted with 50 mL of sterile diluent, yields a 10 mg/mL solution. The label also makes the formulation details impossible to ignore: no preservative, sodium chloride for tonicity, and a pH adjusted to 6.5 to 8.5. For bedside practice, those details matter because leucovorin is often deployed in time-sensitive rescue protocols, where preparation errors can become clinically expensive very quickly.
One sentence captures the drug’s central logic: leucovorin is an antidote to folic acid antagonists.
Reduced Folate Biology Explains Both Rescue and Enhancement
Leucovorin is described as a mixture of diastereoisomers of 5-formyl tetrahydrofolate, but the biologically active compound is the l-isomer. Unlike folic acid, it does not need dihydrofolate reductase to enter folate-dependent one-carbon metabolism. That bypass is the reason it can restore folate pools after methotrexate exposure, when dihydrofolate reductase blockade has left cells unable to regenerate reduced folates efficiently.
The same pathway explains why leucovorin can amplify fluoropyrimidine toxicity and efficacy. In combination with 5-fluorouracil, leucovorin is converted to 5,10-methylenetetrahydrofolate, which stabilizes the binding of fluorodeoxyuridylate to thymidylate synthase. The practical effect is a tighter enzymatic blockade of DNA synthesis and repair. Tumor cells exposed to this combination face a more durable interruption of thymidylate production, which helps explain why the label associates the pairing with improved outcomes in advanced colorectal cancer while also warning of more frequent gastrointestinal toxicity.
The pharmacokinetic profile is fast and clinically relevant. After a 25 mg intravenous dose in male volunteers, serum total reduced folates peaked within 10 minutes, with the initial rise driven by the parent compound. The circulating profile then shifted toward 5-methyltetrahydrofolate, the metabolite that became the dominant form in plasma. The terminal half-life for total reduced folates was 6.2 hours after IV administration, and intramuscular dosing produced a similar overall exposure. Oral administration was also efficient at lower doses, but absorption became saturable above 25 mg, with apparent bioavailability falling as the dose increased. For clinicians, that means route and dose are not interchangeable details; they define how much active folate actually reaches systemic circulation.
Methotrexate Rescue Requires Speed, Monitoring, and Route Discipline
The label is explicit about high-dose methotrexate rescue in osteosarcoma and about rescue after impaired methotrexate elimination or accidental overdose of folic acid antagonists. Timing drives success here. As the interval between antifolate administration and leucovorin rescue lengthens, the ability to blunt toxicity declines. That is not a theoretical caution. It is the difference between restoring healthy folate metabolism in surviving cells and arriving too late to reverse proliferative injury.
Serum methotrexate monitoring is essential for determining leucovorin dose and duration. Delayed methotrexate excretion can occur with third-space fluid accumulation, renal insufficiency, or inadequate hydration, and those situations may require higher doses or prolonged administration. The label also makes a sharp route-specific warning: doses greater than those recommended for oral use must be given intravenously. In practice, this means rescue is not a generic supplement strategy. It is a monitored antidotal intervention tied to pharmacokinetics, kidney function, and the kinetics of methotrexate clearance.
A second safety issue is more direct and more severe: intrathecal administration is prohibited in the rescue of intrathecal antifolate overdose. Leucovorin may be harmful or fatal if given intrathecally. The warning is unusually blunt because the consequence is so severe. In a drug family where timing and route already determine outcome, the wrong compartment can turn an intended rescue into catastrophic harm.
Colorectal Cancer Data Show Clear Activity, Along With More GI Toxicity
The label summarizes two randomized Mayo Clinic and North Central Cancer Treatment Group trials in advanced metastatic colorectal cancer. In the first study, three regimens were compared: high-dose leucovorin with 5-fluorouracil, low-dose leucovorin with 5-fluorouracil, and 5-fluorouracil alone. Response rates were 26%, 43%, and 10%, respectively. Median survival times were 12.2 months, 12 months, and 7.7 months. The low-dose leucovorin arm also produced significant improvement in weight gain of more than 5%, symptom relief, and performance status, while the high-dose arm improved performance status and trended toward better weight gain and symptom control.
The second study replaced the 5-fluorouracil-alone arm with sequential methotrexate, 5-fluorouracil, and leucovorin. Response rates were 31%, 42%, and 14%, respectively, and median survival times were 12.7 months, 12.7 months, and 8.4 months. Those figures show a consistent pattern: leucovorin-containing 5-FU regimens outperformed comparator therapy in tumor response and survival in these trials. The mechanism fits the numbers. By stabilizing thymidylate synthase inhibition, leucovorin deepens fluoropyrimidine effect in a way that can translate into measurable palliative benefit.
The tradeoff is toxicity, especially in the gastrointestinal tract. The label warns that leucovorin enhances 5-fluorouracil toxicity and that 5-FU dosing must therefore be lower than usual when the drugs are administered together. Stomatitis and diarrhea occur more commonly and may be more severe and prolonged with the combination than with 5-FU alone. In the first controlled trial, hospitalization for toxicity occurred in 7% of patients receiving 5-FU alone or 5-FU with high-dose leucovorin, and in 20% of patients receiving 5-FU with low-dose leucovorin. Those numbers are a reminder that biochemical potentiation is clinically double-edged. Tumor kill and mucosal injury travel the same pathway.
Hematologic Rescue Is Not Vitamin B12 Therapy
Leucovorin remains indicated for megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, but the label draws a hard line: it is improper therapy for pernicious anemia and other megaloblastic anemias caused by vitamin B12 deficiency. Hematologic remission can occur while neurologic injury continues to worsen. That warning belongs in every discussion of folate replacement, because correction of blood counts can conceal the ongoing metabolic failure in cobalamin deficiency and delay definitive treatment.
For clinicians, the label ultimately reads as a map of controlled risk. Leucovorin can rescue cells from antifolate injury, support treatment of folate-deficiency anemia, and intensify fluoropyrimidine therapy in metastatic colorectal cancer. The same pharmacology also creates hazards: delayed methotrexate clearance, route-dependent toxicity, and amplified gastrointestinal injury with 5-FU. The label does not soften those tensions. It lays them out in exact biochemical and clinical terms, leaving dosing, timing, and monitoring to carry the burden of safe use.